Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rongbo Lin

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Ebiomedicine|June 25, 2026
A multi-centre, phase 1a/1b dose escalation and expansion study of the HER2-directed antibody-drug conjugate T-Bren (BL-M07D1) in advanced breast cancer and other solid tumoursHerui Yao, Ruihua Zhao, Xiuping Lai, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 3, 2021
Comparing Patient-Controlled Analgesia Versus Non-PCA Hydromorphone Titration for Severe Cancer Pain: A Randomized Phase III TrialRongbo Lin, Sunzhi Lin, Shuitu Feng, et al.
Technology in Cancer Research & Treatment|February 2, 2023
A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: A Clinical Trial ProtocolJinjie He, Yue Liu, Chengcheng Liu, et al.
The Oncologist|January 5, 2021
Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II TrialHuabin Hu, Kun Wang, Meijin Huang, et al.
Experimental Hematology & Oncology|November 22, 2025
Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumorsRongrui Liu, Rongbo Lin, Ning Li, et al.
Nature Communications|January 16, 2026
NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trialChuntao Gao, Yanqiao Zhang, Xiujuan Qu, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 12, 2026
Intravenous Patient-Controlled Analgesia Versus Oral Opioids to Maintain Analgesia for Severe Cancer Pain: A Randomized Phase III TrialRongbo Lin, Lang He, Mingqian Lu, et al.
Nature Medicine|June 1, 2026
Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trialZhi Peng, Tianshu Liu, Hua Wang, et al.
Thoracic Cancer|September 20, 2022
Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in ChinaChunwei Xu, Lu Si, Wenxian Wang, et al.
Global Medical Genetics|February 28, 2024
Expert Consensus on the Diagnosis and Treatment of <i>NRG1/2</i> Gene Fusion Solid TumorsChunwei Xu, Qian Wang, Dong Wang, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Ebiomedicine|June 25, 2026
A multi-centre, phase 1a/1b dose escalation and expansion study of the HER2-directed antibody-drug conjugate T-Bren (BL-M07D1) in advanced breast cancer and other solid tumoursHerui Yao, Ruihua Zhao, Xiuping Lai, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 3, 2021
Comparing Patient-Controlled Analgesia Versus Non-PCA Hydromorphone Titration for Severe Cancer Pain: A Randomized Phase III TrialRongbo Lin, Sunzhi Lin, Shuitu Feng, et al.
Technology in Cancer Research & Treatment|February 2, 2023
A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: A Clinical Trial ProtocolJinjie He, Yue Liu, Chengcheng Liu, et al.
The Oncologist|January 5, 2021
Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II TrialHuabin Hu, Kun Wang, Meijin Huang, et al.
Experimental Hematology & Oncology|November 22, 2025
Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumorsRongrui Liu, Rongbo Lin, Ning Li, et al.
Nature Communications|January 16, 2026
NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trialChuntao Gao, Yanqiao Zhang, Xiujuan Qu, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 12, 2026
Intravenous Patient-Controlled Analgesia Versus Oral Opioids to Maintain Analgesia for Severe Cancer Pain: A Randomized Phase III TrialRongbo Lin, Lang He, Mingqian Lu, et al.
Nature Medicine|June 1, 2026
Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trialZhi Peng, Tianshu Liu, Hua Wang, et al.
Thoracic Cancer|September 20, 2022
Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in ChinaChunwei Xu, Lu Si, Wenxian Wang, et al.
Global Medical Genetics|February 28, 2024
Expert Consensus on the Diagnosis and Treatment of <i>NRG1/2</i> Gene Fusion Solid TumorsChunwei Xu, Qian Wang, Dong Wang, et al.
Pageof 5